Shanghai Fochon Pharmaceutical Co., Ltd.

Fochon Pharmaceuticals, Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Chongqing Fochon Pharmaceutical Co., Ltd.

Fochon Biosciences, Ltd.

Fochon Pharmaceutical Co., Ltd.

Zhifu Li

Weibo Wang

Xingdong Zhao

Haohan Tan

Xianlong Wang

Zuwen Zhou

Jing Sun

Lihua Jiang

Yanxin Liu

Rui Tan

Zhifang Chen

Yue Rong

Hongbin Liu

Huajie Zhang

Tongshuang Li

Weipeng Zhang

Qihong Liu

Min Lin

Chengxi He

Ling Chen

Qiang Tian

Zongyao Zou

Kai Ran

Lijun Yang

Bin Liu

Li Linghu

Fanxin Zeng

Jiemin Fu

Shu Lin

Chuiliang Yu

Yuwei Gao

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Apoptosis-inducing agents

Provided are certain TRK inhibitors of formula (I): pharmaceutical compositions thereof, and methods of use thereof.

Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase

Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders. 

Compounds as BLC-2-selective apoptosis-inducing agents

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Indolizine derivatives, composition and methods of use

Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors

Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof. 

Certain protein kinase inhibitors

Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.

Quinazoline derivatives, compositions thereof, and use as pharmaceuticals

Growing community of inventors

Chongqing, China

Zhifu Li